This summary was created by AI, based on 2 opinions in the last 12 months.
Natera (NTRA-Q) has experienced significant momentum, evidenced by a remarkable 145% increase over the past year. Analysts praise the company's strong positioning in the cancer detection and recurrence testing market, indicating that it possesses a robust franchise in these critical areas. Furthermore, one expert has recently acquired shares, suggesting confidence in the company's growth trajectory and its ability to achieve cash-flow positivity within the year. Overall, both reviews reflect a sense of optimism and long-term faith in Natera's potential to deliver value to shareholders through its innovative biotech solutions in cancer testing.
A biotech that does, among other things, cancer testing which is very accurate.. She just bought it. Is growing fast and expects it to be cash-flow positive this year.
Natera is a American stock, trading under the symbol NTRA-Q on the NASDAQ (NTRA). It is usually referred to as NASDAQ:NTRA or NTRA-Q
In the last year, 2 stock analysts published opinions about NTRA-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Natera.
Natera was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Natera.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Natera In the last year. It is a trending stock that is worth watching.
On 2025-02-12, Natera (NTRA-Q) stock closed at a price of $171.88.
Trimmed it because it moved up 145% the past year. They have a great franchise in cancer detection recurrence. Likes it long-term.